{"id":"W2897161734","doi":"10.1002/cncr.31595","title":"Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium","year":2018,"lang":"en","type":"article","venue":"Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"ca_institutions":"Juravinski Cancer Centre; University of Ottawa; Health Sciences Centre; University of Alberta; Queen Elizabeth II Health Sciences Centre; McMaster University; London Health Sciences Centre; Princess Margaret Cancer Centre","funders":"Foundation Medicine; Novartis Pharma; Genentech; Ipsen; Celldex Therapeutics; Astellas Pharma; Eisai; National Comprehensive Cancer Network; Sanofi; Exelixis; GlaxoSmithKline; Bristol-Myers Squibb; AstraZeneca; Pfizer","keywords":"Medicine; Nivolumab; Renal cell carcinoma; Ipilimumab; Internal medicine; Oncology; Clear cell renal cell carcinoma; Retrospective cohort study; Carcinoma; Cancer; Gastroenterology; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003956678,0.0004747741,0.0005673015,0.0001935261,0.0001228334,0.00005890208,0.0003714417,0.00006000701,0.00060314],"category_scores_gemma":[0.0001187251,0.0002981363,0.0001533216,0.0003913315,0.000369366,0.0002100689,0.0001882659,0.0004413282,0.000114273],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008156525,"about_ca_system_score_gemma":0.0006777261,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006269509,"about_ca_topic_score_gemma":0.001648388,"domain_scores_codex":[0.996466,0.0001807423,0.0008876927,0.0008905924,0.001011882,0.000563056],"domain_scores_gemma":[0.997569,0.0002808377,0.0004593071,0.0009555333,0.0004375726,0.0002977906],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01458626,0.002190907,0.9096789,0.0001990607,0.0005428828,0.001224727,0.005107744,0.0001158035,0.02597157,0.00001921083,0.03865595,0.001706977],"study_design_scores_gemma":[0.0246675,0.00145994,0.6989009,0.0002811083,0.0009595631,0.00001438889,0.000508596,0.0003192856,0.2683743,0.00002592783,0.004014298,0.0004742625],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9912637,0.0009875288,0.00004735813,0.0009062176,0.0006070431,0.00115976,0.001624706,0.00003095496,0.003372674],"genre_scores_gemma":[0.9943523,0.00001836183,0.001769079,0.0006777648,0.0005499439,0.0001783261,0.00137211,0.00007075386,0.001011304],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2424027,"threshold_uncertainty_score":0.9999471,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02731998789822587,"score_gpt":0.2602327787762104,"score_spread":0.2329127908779846,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}